Gaurav Aggarwal - Jan 26, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role: Director, 10%+ Owner
Signature: /s/ Sukhi Jagpal as attorney-in-fact for Gaurav Aggarwal
Stock symbol: SRRA
Transactions as of: Jan 26, 2022
Transactions value $: -$12,871,412
Form type: 4
Date filed: 1/28/2022, 06:53 PM
Previous filing: Jun 9, 2021
Next filing: Jan 31, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRRA	Common Stock	Exercise of in-the-money or at-the-money derivative security	$6.34M	+480K	+33%	$13.20	1.94M	Jan 26, 2022	By Vivo Opportunity Fund, L.P.	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRRA	Series B Warrant (Right to Purchase)	Exercise of in-the-money or at-the-money derivative security	-$19.2M	-1.46M	-100%	$13.20	0	Jan 26, 2022	Common Stock	480K	$13.20	By Vivo Opportunity Fund, L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund, L.P. The Reporting Person may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. with four other managing members of Vivo Opportunity, LLC. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2	The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis.

Content

The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund, L.P. The Reporting Person may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. with four other managing members of Vivo Opportunity, LLC. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis.